继发性甲状旁腺功能亢进热消融治疗专家共识

2021-08-10 中国健康促进基金会 中日友好医院学报

热消融作为肿瘤的微创疗法之一,已在多个实体脏器肿瘤治疗中取得令人满意的疗效。相较其它肿瘤性病变,继发性甲状旁腺功能亢进(简称继发甲旁亢)热消融治疗具有特殊性。慢性肾功能不全患者体质较差,合并继发甲旁亢

中文标题:

继发性甲状旁腺功能亢进热消融治疗专家共识

发布机构:

中国健康促进基金会

发布日期:

2021-08-10

简要介绍:

热消融作为肿瘤的微创疗法之一,已在多个实体脏器肿瘤治疗中取得令人满意的疗效。相较其它肿瘤性病变,继发性甲状旁腺功能亢进(简称继发甲旁亢)热消融治疗具有特殊性。慢性肾功能不全患者体质较差,合并继发甲旁亢疾病病情复杂,围手术期管理需多学科协作,且继发甲旁亢病灶紧邻颈部多个重要结构,对术者消融技术细节要求高,如何做到疗效与安全并重,目前尚无指导性规范。本共识可为相关医生提供全面的技术细节指导,促进继发甲旁亢微创治疗的规范化。

相关资料下载:
[AttachmentFileName(sort=1, fileName=继发性甲状旁腺功能亢进热消融治疗专家共识(2021版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=202f41c00219a360, title=继发性甲状旁腺功能亢进热消融治疗专家共识, enTitle=, guiderFrom=中日友好医院学报, authorId=0, author=, summary=热消融作为肿瘤的微创疗法之一,已在多个实体脏器肿瘤治疗中取得令人满意的疗效。相较其它肿瘤性病变,继发性甲状旁腺功能亢进(简称继发甲旁亢)热消融治疗具有特殊性。慢性肾功能不全患者体质较差,合并继发甲旁亢, cover=https://img.medsci.cn/2021927/1632755798121_5579292.jpg, journalId=0, articlesId=null, associationId=1223, associationName=中国健康促进基金会, associationIntro=中国健康促进基金会 , copyright=0, guiderPublishedTime=Tue Aug 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">热消融作为肿瘤的微创疗法之一,已在多个实体脏器肿瘤治疗中取得令人满意的疗效。相较其它肿瘤性</span><span style="color: #373737;">病变,继发性甲状旁腺功能亢进(简称继发甲旁亢)热消融治疗具有特殊性。慢性肾功能不全患者体质较差,合</span><span style="color: #373737;">并继发甲旁亢疾病病情复杂,围手术期管理需多学科协作,且继发甲旁亢病灶紧邻颈部多个重要结构,对术者</span><span style="color: #373737;">消融技术细节要求高,如何做到疗效与安全并重,目前尚无指导性规范。本共识可为相关医生提供全面的技术</span><span style="color: #373737;">细节指导,促进继发甲旁亢微创治疗的规范化。</span></p>, tagList=[TagDto(tagId=14607, tagName=继发性甲状旁腺功能亢进)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=14607, guiderKeyword=继发性甲状旁腺功能亢进, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3031, appHits=64, showAppHits=0, pcHits=1313, showPcHits=2967, likes=0, shares=4, comments=5, approvalStatus=1, publishedTime=Wed Sep 29 00:47:26 CST 2021, publishedTimeString=2021-08-10, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Sep 27 23:21:25 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 15:11:04 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=继发性甲状旁腺功能亢进热消融治疗专家共识(2021版).pdf)])
继发性甲状旁腺功能亢进热消融治疗专家共识(2021版).pdf
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1080628, encodeId=c38c1080628ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:48:11 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069624, encodeId=a17e106962445, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:45 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055646, encodeId=ce30105564677, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Sep 28 11:40:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055539, encodeId=1a991055539c9, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Tue Sep 28 01:22:10 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055529, encodeId=207c1055529c9, content=涨知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfab5619795, createdName=ms9000000035954032, createdTime=Mon Sep 27 23:51:49 CST 2021, time=2021-09-27, status=1, ipAttribution=)]
    2021-12-16 龙珠

    学习好资料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1080628, encodeId=c38c1080628ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:48:11 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069624, encodeId=a17e106962445, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:45 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055646, encodeId=ce30105564677, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Sep 28 11:40:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055539, encodeId=1a991055539c9, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Tue Sep 28 01:22:10 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055529, encodeId=207c1055529c9, content=涨知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfab5619795, createdName=ms9000000035954032, createdTime=Mon Sep 27 23:51:49 CST 2021, time=2021-09-27, status=1, ipAttribution=)]
    2021-11-12 feifei2511

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1080628, encodeId=c38c1080628ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:48:11 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069624, encodeId=a17e106962445, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:45 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055646, encodeId=ce30105564677, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Sep 28 11:40:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055539, encodeId=1a991055539c9, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Tue Sep 28 01:22:10 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055529, encodeId=207c1055529c9, content=涨知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfab5619795, createdName=ms9000000035954032, createdTime=Mon Sep 27 23:51:49 CST 2021, time=2021-09-27, status=1, ipAttribution=)]
    2021-09-28 ms3000001592172450

    受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1080628, encodeId=c38c1080628ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:48:11 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069624, encodeId=a17e106962445, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:45 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055646, encodeId=ce30105564677, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Sep 28 11:40:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055539, encodeId=1a991055539c9, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Tue Sep 28 01:22:10 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055529, encodeId=207c1055529c9, content=涨知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfab5619795, createdName=ms9000000035954032, createdTime=Mon Sep 27 23:51:49 CST 2021, time=2021-09-27, status=1, ipAttribution=)]
    2021-09-28 海明明

    不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1080628, encodeId=c38c1080628ac, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:48:11 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1069624, encodeId=a17e106962445, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f77d4743066, createdName=feifei2511, createdTime=Fri Nov 12 13:17:45 CST 2021, time=2021-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055646, encodeId=ce30105564677, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee335603873, createdName=ms3000001592172450, createdTime=Tue Sep 28 11:40:23 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055539, encodeId=1a991055539c9, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200720/972f8c2f32a64cd28f904bad3945efc9/3d1556a9e54b4781a5f4968d888e5874.jpg, createdBy=5d015401562, createdName=海明明, createdTime=Tue Sep 28 01:22:10 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055529, encodeId=207c1055529c9, content=涨知识了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfab5619795, createdName=ms9000000035954032, createdTime=Mon Sep 27 23:51:49 CST 2021, time=2021-09-27, status=1, ipAttribution=)]
    2021-09-27 ms9000000035954032

    涨知识了

    0

拓展阅读

2022 AAES指南:继发性和三发性肾性甲状旁腺功能亢进的明确手术治疗

美国内分泌外科协会(AAES,American Association of Endocrine Surgeons) · 2022-07-18

继发性甲状旁腺功能亢进围手术期多学科综合诊治华西共识

四川大学华西医院甲状腺外科 · 2023-02-02